Figure 2. Cumulative overall survival (OS) and recurrence-free survival (RFS) curves of patients with high or low HTATIP2 density and microvessel density (MVD) as well as their combination in cohort 1 (see Results for details).

Patients without sorafenib administration, who possessed (A and B) high HTATIP2 expression or (C and D) low MVD tended to have prolonged OS and RFS. (E and F) The combination of high HTATIP2 expression and low MVD predicted the best survival.